MAC-0040599
MAC-0040599 is a synthetic antibacterial compound that exhibits inhibitory effects against various strains including Burkholderia cenocepacia K56-2 and Pseudomonas aeruginosa. MAC-0040599 can be used in studies related to bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 28783-31-5
- Formula: C6H5NO2S
- Molecular Weight:155.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| C8166 | CC50 |
0.0255 mM
Compound: 1v
|
Cytotoxicity in human C8166 cells
Cytotoxicity in human C8166 cells
|
[PMID: 17574419] |
In Vitro
MAC-0040599 (up to 64 μg/mL; 22 h) inhibits the growth of Burkholderia cenocepacia K56-2 with an MIC of 32 μg/mL, 4 other Bcc strains with MICs ≤32 μg/mL, and Pseudomonas aeruginosa PAO1 with an MIC of 64 μg/mL[1].
MAC-0040599 (48 h) exerts bactericidal activity against 5 of 10 tested Bcc strains at concentrations ≤64 μg/mL[1].
MAC-0040599 (20 h treatment, 1 h Resazurin (HY-118540) incubation) inhibits pre-formed biofilms of Burkholderia cenocepacia K56-2 and 4 other Bcc strains at concentrations ≤64 μg/mL[1].
MAC-0040599 (25-250 μg/mL; 1 h) shows minimal hemolytic activity against sheep red blood cells at concentrations up to 250 μg/mL, with all values below the 5-10% moderate hemolysis threshold[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 28783-31-5
-
Molecular Weight 155.17
-
Formula C6H5NO2S
-
SMILES
O=[N+](/C=C/C1=CSC=C1)[O-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MAC-0040599 Related Classifications
HY-187233 Related Classifications
Powered by Bioz